18.12.2015 - US biopharmaceutical group Amgen is buying back from GlaxoSmithKline (GSK) all of its remaining rights to the bone drugs Prolia (denosumab), Xgeva (denosumab) and Vectibix...
Advertising Opportunities Print, Digital & Content Solutions
LinkedIn | X (Twitter)